NCT01685216 - Efficacy and Safety Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 14, 2012

Primary Completion Date

March 15, 2015

Study Completion Date

March 15, 2015

Conditions

Gaucher Disease, Type 3

Interventions

BIOLOGICAL

velaglucerase alfa

lyophilized powder, intravenous infusion, units, Every other week (EOW)

Trial Locations (5)

Hospital La Rabta, Tunis

Alexandria University Hospital, Alexandria

Abu El Rich Hospital, Cairo University Hospital, Cairo

Children's Hospital, Ain Shams University Hospital, Cairo

KEM Hospital Research Centre, Pune